Skip to Main Content

Everyone needs a backup plan, including one of the biggest biotech companies in town. So when Biogen earlier this year gave up on turning a profit from its beleaguered Alzheimer’s drug, Aduhelm, the Cambridge company moved its chips to another experimental Alzheimer’s treatment.

The new drug, called lecanemab, could be safer and provide more obvious benefits than its controversial predecessor, and Biogen expects results from an advanced clinical trial this fall. And, as was once said of Aduhelm, the outcome of the lecanemab trial will be crucial for Biogen’s future.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment